# US 2021/0070864 A1 · Hla-g as a novel target for car t-cell immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0070864 A1
- Document ID: US20210070864A1
- Status: Published application
- Kind: A1
- Application number: 16/841,810
- Filed: 2020-04-07
- Published: 2021-03-11
- Earliest claimed: 2015-03-27
- Assignees: University of Southern California
- Applicants: University of Southern California
- Inventors: Alan L. Epstein; Peisheng Hu
- Web page: https://patentgrep.com/patent/US20210070864A1

## CPC

- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 39/001111: {Immunoglobulin superfamily}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/57545: of the ovaries
- G01N 33/57555: of the prostate
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

CAR cells targeting and antibodies human HLA-G are described as a new method of cancer treatment. It is proposed that HLA-G CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-G.

## Claims

### Claim 1

An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the antibody binds to an epitope of HLA-G comprising the amino acid sequence SEQ ID NO: 30, or an equivalent thereof, wherein the HC immunoglobulin variable domain sequence comprises a CDRH1 sequence comprising GFNIKDTY (SEQ ID NO: 1) or GFTFNTYA (SEQ ID NO: 2) or an equivalent of each thereof, a CDRH2 sequence comprising IDPANGNT (SEQ ID NO: 3) or IRSKSNNYAT (SEQ ID NO: 4) or an equivalent of each thereof, and a CDRH3 sequence comprising ARSYYGGFAY (SEQ ID NO: 5) or VRGGYWSFDV (SEQ ID NO: 6) or an equivalent of each thereof, wherein the LC immunoglobulin variable domain sequence comprises a CDRL1 sequence comprising KSVSTSGYSY (SEQ ID NO: 11) or KSLLHSNGNTY (SEQ ID NO: 12) or an equivalent of each thereof, a CDRL2 sequence comprising LVS (SEQ ID NO: 13) or RMS (SEQ ID NO: 14) or an equivalent of each thereof, a CDRL3 sequence comprising QHSRELPRT (SEQ ID NO: 15) or MQHLEYPYT (SEQ ID NO: 16) or an equivalent of each thereof, wherein an equivalent has at least 80% amino acid identity to the sequence, or is encoded by a polynucleotide that is at least 80% identical to a polynucleotide encoding the sequence.

### Claim at position 2

2-8. (canceled)

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the HC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 8 or 10, or an equivalent of each thereof, or wherein the LC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 18 or 20, or an equivalent of each thereof, wherein an equivalent has at least 80% amino acid identity to the sequence, or is encoded by a polynucleotide that is at least 80% identical to a polynucleotide encoding the polypeptide.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The antibody of claim 1, wherein the HC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 8 or 10, and wherein the LC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 18 or 20, or an equivalent of each thereof, wherein an equivalent has at least 80% amino acid identity to the sequence, or is encoded by a polynucleotide that is at least 80% identical to a polynucleotide encoding the polypeptide.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

An antigen binding fragment of the antibody of claim 1, wherein the antigen binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, scFv, and Fv.

### Claim 14 (depends on 1)

An isolated ex vivo complex comprising the antibody of claim 1 or an antigen binding fragment thereof, and optionally a detectable label.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of detecting HLA-G in a biological sample comprising contacting the sample with the antibody of claim 1 or an antigen binding fragment thereof, and detecting a complex formed by the binding of the antibody or antigen binding fragment to HLA-G.

### Claim at position 11

17-20. (canceled)

### Claim 21 (depends on 1)

A method of detecting a pathological cell in a sample isolated from a subject, comprising
(a) detecting the level of HLA-G in a biological sample from the subject by detecting a complex formed by the antibody of claim 1 or an antigen binding fragment thereof binding to HLA-G in the sample; and
(b) comparing the levels of HLA-G observed in step (a) with the levels of HLA-G observed in a control biological sample;
wherein the pathological cell is detected when the level of HLA-G is elevated compared to that observed in the control biological sample and the pathological cell is not detected when the level of HLA-G is not elevated as compared to the observed in the control biological sample.

### Claim at position 13

22-27. (canceled)

### Claim 28 (depends on 1)

A kit for detecting HLA-G comprising an antibody of claim 1 or an antigen binding fragment thereof, and instructions for use.

### Claim 29 (depends on 16)

The method of claim 16, wherein the biological sample is a tumor sample.

### Claim 30 (depends on 1)

A chimeric antigen receptor (CAR) comprising: (a) an antigen binding domain of an anti-HLA-G antibody of claim 1; (b) a CD8 α hinge domain; (c) a CD8 α transmembrane domain; (d) a CD28 costimulatory signaling region and/or a 4-1BB costimulatory signaling region; and (e) a CD3 zeta signaling domain.

### Claim at position 17

31-33. (canceled)

### Claim 34 (depends on 30)

The CAR of claim 30, wherein the HC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 8 or 10, or an equivalent of each thereof, or wherein the LC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 18 or 20.

### Claim 35

(canceled)

### Claim 36 (depends on 30)

The CAR of claim 30, wherein the HC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 8 or 10, and wherein the LC immunoglobulin variable domain sequence comprises the amino acid sequence of SEQ ID NOs: 18 or 20, or an equivalent of each thereof.

### Claim at position 21

37-42. (canceled)

### Claim 43 (depends on 30)

A vector comprising a nucleic acid sequence encoding the CAR of claim 30.

### Claim at position 23

44-45. (canceled)

### Claim 46 (depends on 1)

An isolated cell comprising one or more of:
the antibody of claim 1 or an antigen binding fragment thereof;
a nucleic acid encoding the antibody or the antigen binding fragment thereof, or a complement thereof;
a complex comprising the antibody or the antigen binding fragment thereof;
a CAR comprising: (a) the antigen binding domain of the antibody, (b) a CD8 α hinge domain, (c) a CD8 α transmembrane domain, (d) one or both of a CD28 costimulatory signaling region or a 4-1BB costimulatory signaling region, and (e) a CD3 zeta signaling domain;
a nucleic acid encoding the CAR or a complement thereof, or
a vector comprising one or more of: the nucleic acid encoding the antibody or the antigen binding fragment thereof, the nucleic acid encoding the CAR, or a complement of each thereof.

### Claim 47 (depends on 46)

The isolated cell of claim 46, wherein the cell is a T-cell or an NK-cell.

### Claim 48

(canceled)

### Claim 49 (depends on 1)

An isolated nucleic acid encoding the isolated antibody of claim 1 or an antigen binding fragment thereof; or encoding a CAR comprising: (a) the antigen binding domain of the antibody, (b) a CD8 α hinge domain, (c) a CD8 α transmembrane domain, (d) one or both of a CD28 costimulatory signaling region or a 4-1BB costimulatory signaling region, and (e) a CD3 zeta signaling domain; or its complement.

### Claim 50

(canceled)

### Claim 51 (depends on 30)

A method of producing HLA-G CAR expressing cells comprising:
(i) transducing a population of isolated cells with a nucleic acid sequence encoding the CAR of claim 30; and
(ii) selecting a subpopulation of said isolated cells that have been successfully transduced with said nucleic acid sequence of step (i) thereby producing HLA-G CAR expressing cells.

### Claim 52

(canceled)

### Claim 53 (depends on 47)

A method of inhibiting the growth of a tumor in a subject in need thereof, comprising administering to the subject an effective amount of the isolated cell of claims 47.

### Claim at position 32

54-57. (canceled)

### Claim 58 (depends on 47)

A method of treating a cancer patient in need thereof, comprising administering to the subject an effective amount of the isolated cell of claim 47.

### Claim at position 34

59-62. (canceled)

### Claim 63

A method for determining if a patient is likely to respond or is not likely to HLA-G CAR therapy, comprising contacting a tumor sample isolated from the patient with an effective amount of an anti-HLA-G antibody and detecting the presence of any antibody bound to the tumor sample, wherein the presence of antibody bound to the tumor sample indicates that the patient is likely to respond to the HLA-G CAR therapy and the absence of antibody bound to the tumor sample indicates that the patient is not likely to respond to the HLA-G therapy.

### Claim 64

(canceled)
